Drug intelligence / Profile preview

paroxetine + triiodothyronine

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy using paroxetine, a selective serotonin reuptake inhibitor (SSRI), and triiodothyronine (T3), a thyroid hormone. This combination is primarily used as an augmentation strategy for treatment-resistant depression. Paroxetine works by inhibiting the reuptake of serotonin in the brain, while T3 is thought to enhance serotonergic neurotransmission. The addition of T3 to antidepressants like paroxetine may improve treatment response in some patients with major depression, particularly those who have not responded adequately to SSRI monotherapy.

Other names: T3 augmentation of paroxetineT-3 augmentation of paroxetineT 3 augmentation of paroxetine

Targets

SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on paroxetine + triiodothyronine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on paroxetine + triiodothyronine.

Explore the full profile